These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 34281875

  • 1. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.
    Hashimoto S, Nagai M, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2021 Aug; 41(8):4061-4070. PubMed ID: 34281875
    [Abstract] [Full Text] [Related]

  • 2. Growth Suppression of Human Colorectal Cancer Cells with Mutated KRAS by 3-Deaza-cytarabine in 3D Floating Culture.
    Luo H, Nishi K, Ishikura S, Swain A, Morishige N, Yazaki R, Ohshima T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2018 Jul; 38(7):4247-4256. PubMed ID: 29970558
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S.
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [Abstract] [Full Text] [Related]

  • 6. MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS.
    Nishi K, Tsunoda T, Uchida Y, Sueta T, Sawatsubashi M, Yamano T, Hashiguchi Y, Swain A, Shirasawa S, Sakata T.
    Anticancer Res; 2020 Aug; 40(8):4687-4694. PubMed ID: 32727793
    [Abstract] [Full Text] [Related]

  • 7. Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
    Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory Effect of Pyra-Metho-Carnil on Cancer Spheroid Growth Through Decrease in Glycolysis-associated Molecules.
    Yoshida K, Nishi K, Ishikura S, Matsumoto T, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2023 Aug; 43(8):3717-3726. PubMed ID: 37500165
    [Abstract] [Full Text] [Related]

  • 9. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

  • 10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 11. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y.
    Mol Cell Biochem; 2018 May 14; 442(1-2):39-45. PubMed ID: 28936721
    [Abstract] [Full Text] [Related]

  • 12. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.
    Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.
    Br J Cancer; 2019 Jul 14; 121(1):37-50. PubMed ID: 31133691
    [Abstract] [Full Text] [Related]

  • 13. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B, Wu J, Zhang S.
    Tumour Biol; 2015 May 14; 36(5):3301-8. PubMed ID: 25524577
    [Abstract] [Full Text] [Related]

  • 14. Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures.
    Nakano T, Kanai Y, Amano Y, Yoshimoto T, Matsubara D, Shibano T, Tamura T, Oguni S, Katashiba S, Ito T, Murakami Y, Fukayama M, Murakami T, Endo S, Niki T.
    PLoS One; 2017 May 14; 12(8):e0181342. PubMed ID: 28786996
    [Abstract] [Full Text] [Related]

  • 15. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH.
    Int J Mol Sci; 2019 Nov 24; 20(23):. PubMed ID: 31771279
    [Abstract] [Full Text] [Related]

  • 16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 17. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.
    J Exp Clin Cancer Res; 2019 Jan 28; 38(1):41. PubMed ID: 30691487
    [Abstract] [Full Text] [Related]

  • 18. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V.
    Clin Cancer Res; 2015 Mar 01; 21(5):1087-97. PubMed ID: 25248381
    [Abstract] [Full Text] [Related]

  • 19. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
    Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S.
    Oncotarget; 2014 May 15; 5(9):2807-19. PubMed ID: 24798549
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory Effect of Pyra-Metho-Carnil on the Differentiation and Maturation of Macrophages in Normal and Cancer Microenvironments.
    Kitaguchi T, Matsumoto T, Yoshida K, Hamaguchi Y, Maruta G, Maeoka H, Ishikura S, Nakano M, Ishida Y, Hirai F, Aoki M, Kodama S, Shirasawa S, Tsunoda T.
    Anticancer Res; 2024 Aug 15; 44(8):3557-3565. PubMed ID: 39060056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.